Zanzalintinib maintenance for high-grade neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called zanzalintinib as a maintenance therapy to keep high-grade neuroendocrine tumors from growing after chemotherapy. It may be a good option if you've had success with chemotherapy and are ready for a treatment break.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-grade neuroendocrine tumor (a fast-growing type of cancer from hormone-producing cells).
- You have completed at least 2 rounds of chemotherapy and your most recent scan showed your tumor is stable or smaller.
- You are 18 or older and able to do daily activities with little help.
- Your blood counts, liver, and kidney function are within certain limits.
- You haven't taken zanzalintinib or cabozantinib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called zanzalintinib for adults with a rare type of tumor called pheochromocytoma or paraganglioma that has spread or cannot be removed with surgery. The goal is to see if this drug can slow or stop the tumor from growing, and to evaluate its safety.
This trial tests a new drug, zanzalintinib, for people with adenoid cystic carcinoma that has come back or spread and can't be treated with local therapy. The drug may help slow or stop the cancer's growth.
This study tests a new oral medication called zanzalitinib, which may help slow the growth of advanced prostate cancer that has continued to spread despite hormone therapy and possibly chemotherapy. The goal is to see if the drug is safe and effective for men with this type of cancer.
This trial tests a maintenance therapy combining zanzalintinib and etoposide after you've completed high-dose chemotherapy and a stem cell transplant for germ cell cancer. The goal is to see if this drug combination helps prevent the cancer from coming back.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has grown after at least one prior treatment. The drug may help shrink tumors or slow their growth.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Hear when a new High Grade Neuroendocrine Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.